Results 1 to 1 of 1

Thread: Cytogenetics in Hematologic Malignancies

  1. #1

    Default Cytogenetics in Hematologic Malignancies

    Example, Acute Myeloid Leukemia

    Slovak et al., stratified patients with AML into four risk categories.

    Those in the favorable group had inv(16), t(15;17) or t(8;21).

    While those in the unfavorable group had monosomy 5/5q deletion, monosomy 7/7q deletion, inv(3), 11q23 rearrangements, abnormalities of 17p, 20q or 21q, t(6;9), or complex karyotypes (with 3 or more abnormalities)

    Those in the intermediate group had a normal karyotype, trisomy 8, trisomy 6, deletion of the 12p, or loss of the Y chromosome.

    There was also an indeterminant group that contained all other chromosome anomalies.

    Grimwade et al. proposed a slightly different prognostic classification scheme.

    Individuals with inv(16), t(15;17) or t(8;21) were in the favorable group.

    Those in the adverse group included abnormalities of 3q [excluding t(3;5)(q21-25;q31-35)], inv(3), monosomy 5/5q deletion, monosomy 7/7q deletion, t(6;11), t(10;11), 11q23 rearrangements [excluding t(9;11) and t(11;19)], t(9;22), monosomy 17/abnormalities of 17p, and complex karyotypes (with 4 or more abnormalities).

    All others fell into the intermediate group

    Cytogenetics in Hematologic Malignancies-screen-shot-2016-06-12-at-10-39-20-pm-png
    Last edited by CheneyHsiung; Mon 13th June '16 at 3:29pm.
    Clinical Pharmacy Specialist - Hematology

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts